论文部分内容阅读
目的 CT导向下125I放射性粒子植入治疗膈顶部原发性肝癌的可行性、安全性及有效性。方法自2006年1月~2011年10月,共收集46例无法手术切除的膈顶部原发性肝癌患者,共膈顶部病变49个。根据术前强化CT利用TPS计划系统设定125I剂量和分布在CT导向下行125I粒子植入。125I处方剂量(匹配周边剂量):150~200Gy。结果本组46例患者均按计划顺利完成介入治疗。平均植入125I粒子65.6粒。3、6、9、12个月的肿瘤局疗控制率(CR+PR)分别为30.6%、69.4%、55.3%及46.3%(P<0.05)。无严重并发症发生。结论 CT导向介入治疗膈顶部原发性肝癌是一种安全、有效的微创局部治疗手段。
Objective CT-guided 125I radioactive particle implantation in the treatment of primary hepatic carcinoma of diaphragm is feasible, safe and effective. Methods From January 2006 to October 2011, a total of 46 unresectable patients with primary hepatic carcinoma of the diaphragm were collected, and 49 of the total mediastinal lesions were collected. According to the preoperative enhanced CT, the TPS planning system was used to set the dose and distribution of 125I to CT guided 125I seed implantation. 125I prescription dose (matching peripheral dose): 150 ~ 200Gy. Results The group of 46 patients completed the planned intervention successfully. An average of 65.6 125I seeds were implanted. The tumor control rates (CR + PR) at 3, 6, 9 and 12 months were 30.6%, 69.4%, 55.3% and 46.3% respectively (P <0.05). No serious complications occurred. Conclusion CT-guided percutaneous transhepatic primary hepatocellular carcinoma is a safe and effective minimally invasive local treatment.